Skip Navigation

European Heart Journal 1985 6(11):930-938;
Copyright © 1985 by the European Society of Cardiology.
This Article
Right arrow Full Text (PDF)
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by SILKE, B.
Right arrow Articles by TAYLOR, S.H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by SILKE, B.
Right arrow Articles by TAYLOR, S.H.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 1985 The European Society of Cardiology

Haemodynamic analysis of the effects of nicardipine and metoprolol alone and in combination in coronary artery disease

B. SILKE, S.P. VERMA, M.A. FRAIS, G. REYNOLDS, N. JACKSON and S.H. TAYLOR

University Department of Cardiovascular Studies. The General Infirmary at Leeds Leeds, U.K.

Received 9 May 1985; revised 17 July 1985; .

Address for Correspondence:Dr B. Silke, The General Infirmary at Leeds, Leeds, LSI 3EX, U.K.

Abstract

The circulatory consequences of concurrent slow-calcium channel (nicardipine) and cardioselective beta blockade (metoprolol) were evaluated in 20 patients with angiographically proven coronary artery disease. The rest and exercise haemodynamic impact of intravenous nicardipine (10mg) or metoprolol (10mg) alone was determined by randomly allocating 10 patients to each drug; finally all patients were assessed on combination therapy. The plasma levels of nicardipine (17 ±3 to 53 ±6 ng ml-1) and metoprolol (36 ±5 to 97 ± 16 ng ml-1) achieved at the time of each study were in the established therapeutic range.At rest nicardipine reduced systemic mean arterial pressure and systemic vascular resistance index; cardiac and stroke volume indices increased without change in pulmonary artery occluded pressure. Metoprolol alone reduced systemic blood pressure, heart rate and cardiac index, and increased systemic vascular resistance index. Combination therapy reduced systemic arterial blood pressure and heart rate with relatively modest effects on cardiac index, systemic vascular resistance index and pulmonary artery occluded pressure.During dynamic exercise nicardipine reduced systemic mean and diastolic arterial pressure and stroke work index without change in other haemodynamic variables. Metoprolol reduced exercise systemic arterial pressures, heart rate and cardiac index, and increased systemic vascular resistance index and pulmonary artery occluded pressure. Combination therapy produced changes similar to those at rest; at peak nicardipine pharmacodynamic activity, the cardiac depressant actions of metoprolol were largely offset by the induced reduction in left ventricular afterload.Thus these data suggest that nicardipine is safe to use concurrently with cardioselective beta-adrenoceptor blockade; moreover it may prove useful in offsetting some of the adverse haemodynamic effects of beta-blocking drugs in patients with severe coronary artery disease.

Key Words: Haemodynamics • coronary artery disease • nicardipine, metoprolol


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.